EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

BenzingaMay 6 07:16 ET

Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Preclinical Data Supports the Advancement of Oral Ketamir-2 as a Safe, Next-generation Alternative to Ketamine, With Ongoing Momentum in Phase I Clinical Trial Enrollment'

BenzingaMay 6 07:15 ET

Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Reports No Brain Toxicity In FDA-Required Study Of Ketamir-2, Says Confirming Absence Of Ketamine-Linked Neurotoxicity

BenzingaMay 6 07:15 ET

MIRA Pharmaceuticals Announced A Key Development Milestone For Its Novel Topical Formulation Of Ketamir-2 Demonstrated Successful, Dose-proportional Drug Release In A Validated Laboratory Study-8K

BenzingaApr 23 07:42 ET

Express News | Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment

BenzingaApr 22 11:11 ET

Is Mira Pharmaceuticals Gaining or Losing Market Support?

BenzingaApr 17 13:01 ET

BriaCell Therapeutics BCTX Phase 2 Survivor Data; MIRA Pharmaceuticals MIRA Preclinical Ketamine

BioPharmCatalystApr 16 16:13 ET

Sector Update: Health Care Stocks Slide Late Afternoon

MT NewswiresApr 16 15:59 ET

Top Midday Gainers

MT NewswiresApr 16 14:05 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaApr 16 08:07 ET

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

AccesswireApr 16 08:00 ET

Express News | Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025

ReutersApr 16 07:32 ET

Express News | Mira Pharmaceuticals Inc - Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms - SEC Filing

ReutersApr 16 07:32 ET

Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, With Some Subjects Achieving Complete Symptom Reversal'

BenzingaApr 16 07:15 ET

Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Announces Positive Results For Ketamir-2 In Diabetic Neuropathy Animal Model, Says Reinforcing Confidence Ahead Of Phase I Completion

BenzingaApr 16 07:15 ET

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

BenzingaApr 16 07:15 ET

MIRA Pharmaceuticals | 10-K/A: Annual report (Amendment)

SECApr 15 17:15 ET · Announcements

AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."

① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.

cls.cnApr 11 07:59 ET

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

AccesswireApr 1 08:00 ET

Express News | Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing

ReutersApr 1 07:32 ET